Safety Study of Recombinant Vaccinia Virus Administered Intravenously in Patients With Metastatic, Refractory Colorectal Carcinoma

PHASE1CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

July 31, 2010

Primary Completion Date

November 30, 2012

Study Completion Date

December 31, 2015

Conditions
Carcinoma, Colorectal
Interventions
DRUG

Recombinant Vaccinia GM-CSF; RAC VAC GM-CSF (JX-594)

Intravenous Dose Range: 1x10\^6 pfu/kg, 1x10\^7 pfu/kg, 3x10\^7 pfu/kg Up to 4 intravenous infusions administered over 60 minutes every 2 weeks.

Trial Locations (1)

Unknown

Samsung Medical Center, Seoul

Sponsors
All Listed Sponsors
collaborator

Samsung Medical Center

OTHER

lead

Jennerex Biotherapeutics

INDUSTRY

NCT01380600 - Safety Study of Recombinant Vaccinia Virus Administered Intravenously in Patients With Metastatic, Refractory Colorectal Carcinoma | Biotech Hunter | Biotech Hunter